<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03516526</url>
  </required_header>
  <id_info>
    <org_study_id>NL56584.029.16</org_study_id>
    <nct_id>NCT03516526</nct_id>
  </id_info>
  <brief_title>Towards Personalized Dosing of Natalizumab in Multiple Sclerosis</brief_title>
  <acronym>PDNMS</acronym>
  <official_title>Towards Personalized Dosing of Natalizumab in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanquin Plasma Products BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OLVG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective clinical trial with the aim of maintaining drug efficacy of natalizumab while
      extending dose intervals guided by drug concentrations in patients with relapsing remitting
      multiple sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our main objective is to prove that extending dose intervals guided by natalizumab serum
      concentrations, will not result in radiological or clinical disease activity in completely
      stable RRMS patients treated with natalizumab. Adult patients with RRMS with no evident
      disease activity during the last 12 months of natalizumab infusions with a minimum treatment
      of 12 months wil be included. Before subsequent natalizumab infusions, serum concentrations
      will be evaluated. If the concentration exceeds 15μg/ml the dose interval will be extended
      with a week to a maximum of eight weeks. Patients will get regular brain MRI scans and
      clinical follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2016</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 21, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gadolinium enhancing T1 lesions on brain MRI</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence and number of gadolinium enhancing T1 lesions of brain MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New T2 lesions on brain MRI</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence and number of new T2 lesions on brain MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapses</measure>
    <time_frame>12 months</time_frame>
    <description>scoring MS exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS</measure>
    <time_frame>12 months</time_frame>
    <description>Expanded Disability Status Scale: clinical scoring of disability in MS patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSFC</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Multiple Status Functional Composite: clinical scoring of disability in MS patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient perspective measured with the SF-36</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>questionnaire: Short Form-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient perspective measured with the MSIS-29</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>questionnaire: Multiple Sclerosis Impact Scale-29</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>All patients in this study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with natalizumab with a minimum of 1 year, without signs of disease activity (relapses, new T2 lesions on MRI) for a minimum of 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natalizumab</intervention_name>
    <description>Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations</description>
    <arm_group_label>All patients in this study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing-remitting multiple sclerosis (RRMS) according to the McDonald criteria,
             revised by Polman 2010

          -  Natalizumab treatment for 12 months or longer at inclusion.

          -  An expanded disability status scale (EDSS) score of 0.0-6.0 at baseline.

          -  Natalizumab level of ≥15 μg/ml

          -  Written informed consent.

        Exclusion Criteria:

          -  Any MS disease activity (radiologically or clinically) during the last 12 months of
             natalizumab treatment.

          -  Unable to undergo frequent MRI.

          -  The use of other immunomodulatory medication other than natalizumab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joep Killestein, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU medical center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus medical center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Zoé van Kempen</investigator_full_name>
    <investigator_title>Coordinating investigator</investigator_title>
  </responsible_party>
  <keyword>natalizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

